Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
23,543.60
(
0.00%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
92.96
(
-8.16%
)
Bitcoin
71,730.00
(
-0.36%
)
News Focus
News Focus
Post# of 57675
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

neuroinv

Send PM Follow Ignore
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

neuroinv

Re: atheroprevent post# 17222

Friday, 05/16/2008 12:35:29 AM

Friday, May 16, 2008 12:35:29 AM

Post# of 57675
The interesting subtext is that Lilly's current lead glutamatergic mechanism is via mGluR: wherein their lead compound did not equal Zyprexa's efficacy in Phase II; and their head mGluR guy left and went to Merck.


NeuroInvestment
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today